Tyvaso Inhaled denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for tyvaso inhaled are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applies Quantity Limits to Tyvaso (Inhaled Treprostinil)

Cigna's formulary management includes quantity-limit edits on specialty drugs, including Tyvaso (inhaled treprostinil). A quantity-limit denial means the amount requested — whether in cartridges, ampules, or device supplies — exceeds the default amount Cigna's system will auto-approve. This often happens when a patient is titrating to a therapeutic dose, has higher-than-average clinical need, or is transitioning between delivery devices.

Quantity-limit denials are highly appealable. Unlike a formulary exclusion, the drug is acknowledged as covered — the dispute is only about the amount. Demonstrating medical necessity for the prescribed quantity is typically sufficient for reversal.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): File within the deadline stated on the denial notice. Most plans allow 180 days from denial.
• Expedited review: If running out of medication poses an urgent clinical risk (which is likely for PAH patients), request expedited internal review and simultaneously request expedited external review.
• External review: If internal appeal fails, request IRO review within approximately four months of the internal denial. Quantity-limit overrides are a routine and frequently granted category of external review.

## Documentation to Gather

1. Current prescription: The exact quantity prescribed, with the prescriber's notation of clinical rationale for that quantity. 2. Titration or dose-adjustment records: If the quantity exceeds the default because of titration, provide the titration schedule from the chart and the prescriber's explanation of why this phase requires a higher quantity. 3. Device and administration records: For inhaled treprostinil, document the delivery device in use (nebulizer vs. dry powder inhaler) and any supply requirements specific to that device. 4. Clinical necessity letter: The prescriber should explain — without referencing specific mg numbers in the appeal, but by citing the FDA-approved prescribing information — that the prescribed quantity is consistent with the labeled dosing range and the patient's individualized treatment plan. 5. Waste or spillage documentation: If applicable, document any clinically required waste (e.g., single-use vials, preparation loss) that contributes to higher apparent quantity.

## Criteria-Mapping Strategy

Obtain Cigna's current quantity-limit policy for inhaled treprostinil (from the formulary or coverage policy library). Compare the stated limit to the prescription. In the appeal letter, explain precisely why the patient's clinical circumstances require the prescribed quantity, using chart documentation. Reference the FDA prescribing information's dosing guidance as the authoritative source for what quantities are clinically appropriate, and direct the reviewer to match the patient's titration status against that guidance.